Facebook
Twitter
LinkedIn
Forward2014 Wisconsin Dermatological Society Fall Meeting
This educational activity is designed to enhance the knowledge of the academic and community dermatologists in Wisconsin. The 2014 Wisconsin Dermatological Society Fall Meeting will include four expert lectures on topics including allergic contact dermatitis, system treatments for pediatric patients, pathogenesis and treatment of alopecia areata and vitiligo, and a clinical-histopathologic correlation session on neutrophilic urticarial dermatosis.
In addition, virtual patient case presentations will be given highlighting rare and common conditions, as well as threatments. These patient cases have been selected to demonstrate key points in patient diagnosis mangement and will emphasize application of evidence-based medicine and up-to-date references.
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 4.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 4.25 hours of participation for continuing education for allied professionals.
Target Audience
Dermatologists
Dermatopathologists
Dermatologic Surgeons
Nurse Practitioners
Physicians Assistants
Dermatology Residents
WDS Members
Other Allied Healthcare Providers who work with patients that have dermatologic diseases
Learning Objectives
John Harris, MD, PhD
- What is the safety and efficacy of available treatments for vitiligo and alopecia areata?
- How should unusual presentations of vitiligo and alopecia areata affect your management approach?
- What are the treatments of the future for vitiligo and alopecia areata?
Elaine Siegfried, MD
- To be aware of standard-of-care systemic treatment options for severe skin disease in children.
- To be familiar with challenges faced by industry in developing new drugs for children with severe skin disease.
- To learn about new molecular entities in development of children with severe skin disease.
Keri Chaney, MD
- Review common cosmetic contact allergens and discuss strategies on how to avoid them in the products we recommend and prescribe to patients.
- Discuss glove allergic contact dermatitis and how healthcare workers can avoid rubber accelerators.
- Present cases other than allergic contact dermatitis where patch testing may be useful.
Olayemi Sokumbi, MD
- Describe the histologic spectrum of neutrophilic urticarial dermatosis.
- Discuss the clinical spectrum behind the histologic reaction pattern.
- Establish the importance of clinicopathologic correlation in reaching a final diagnosis
Shelly Martin, Dawn Siegel, MD; Keri Chaney, MD; Olayemi Sokumbi, MD; Megan Dowling, MD; Stephen Humphrey, MD; Marianne Junck, MD; Ashley Sullivan, MD; Michelle Bayer, MD; Dianne de Leon, MD; Amy Wentland, MD; JiaDe Yu, MD; Brianne Dickey, MD; Daniel Hekman, MD; Eun-Kyung Kwon, MD; Molly Ness, MD; Allison Schaus, MD; Rachel Collins, PA-C
All persons in control of content have NO relevant financial relationships to disclose with the exception of:
Sam Hwang, MD, PhD Novarits, Abbvie
Barbara Wilson, MD Carma Labs
John Harris, MD, PhD Genzyme, Abbvie, Combe
Elaine Siegfried, MD Anacor, Promius, Galderma, Novartis, Pierre-Fabre
In accordance with the ACCME® standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
Available Credit
- 4.25 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 4.25 Hours of ParticipationHours of Participation credit.